In cancer, CD151 and CD56 / CD106 are jointly upregulated [93, 94], CD106 upregulation proceeding via the impact of CD151 on MET signaling [94], CD151-dependent activation of MET signaling in promoting motility being also described for EC [94], and a CD151-CD49c or -CD49f complex promotes motility of breast cancer cells via MET activation [74], which may also account for CD56. Here, CD151 is linked to breast carcinoma.